Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026

Nuvation Bio (NUVB) will discuss third-quarter 2026 financial results and business updates on a conference call on November 4, 2026.

Rhea-AI Summary

Nuvation Bio (NUVB) will discuss third-quarter 2026 financial results and business updates on a conference call on November 4, 2026. The call and live webcast will begin at 4:30 p.m. ET. Investors and the public can register through the company's Investor Relations website. An archived recording will remain available on its website for 90 days after the event.

Argus Oct 22 session 3 alerts

-3.09% close to close 6.6x rel. volume Open Argus

Details

Market move: NUVB -3.09% in the Oct 22 session. 3Q26 earnings report

-4.1% Trough Tracked

$1.70B Mkt Cap at Peak Alert

On Oct 22, the first trading day after this news, NUVB closed 3.09% below the previous close. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner recorded 3 alerts for this stock that day. Relative volume reached 6.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Oct 22 session.

Key Figures

Business update call: November 4, 2026, 4:30 p.m. ET

Business update call

November 4, 2026, 4:30 p.m. ET

Third-quarter 2026 financial results and business update

Key Terms

ros1 inhibitor, idh1 inhibitor, drug-drug conjugate

3 terms

ros1 inhibitor medical

"a next-generation ROS1 inhibitor"

A ROS1 inhibitor is a targeted small-molecule drug that blocks the activity of the ROS1 receptor tyrosine kinase, an enzyme that can drive cancer cell growth when the ROS1 gene is abnormally fused or rearranged. By binding to the kinase’s active site, these inhibitors prevent the signaling that promotes tumor cell proliferation and survival; their clinical effect is generally limited to cancers that carry ROS1 rearrangements, and tumor resistance can emerge through secondary mutations or alternative signaling pathways.

idh1 inhibitor medical

"a brain-penetrant IDH1 inhibitor"

A small-molecule drug that binds to and blocks the activity of the isocitrate dehydrogenase 1 (IDH1) enzyme, usually targeting the cancer-associated mutant form of IDH1. Mutant IDH1 produces an abnormal metabolite (2‑hydroxyglutarate) that disrupts cell differentiation; an IDH1 inhibitor reduces that oncometabolite and can restore more normal cellular behavior. Effectiveness depends on the presence of an IDH1 mutation in the tumor—these drugs generally do not work against cancers with only the normal (wild‑type) IDH1 enzyme.

drug-drug conjugate medical

"an innovative drug-drug conjugate (DDC) program"

A drug-drug conjugate is a single chemical product in which two active drug molecules are joined together so they travel and act as one therapy. Think of it like two tools taped together to reach a hard-to-get job: the linked drugs can improve delivery to target tissue, enhance effectiveness, or reduce side effects compared with giving each drug separately. For investors it signals higher potential reward but also added scientific, manufacturing and regulatory complexity that can affect development timelines and costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2026.

Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter access code 480 013 916. An archived recording will be available on Nuvation Bio's website for 90 days following the event.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Media and Investor Contacts

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-report-third-quarter-2026-financial-results-and-provide-business-update-on-november-4-2026-302915774.html

SOURCE Nuvation Bio, Inc.